

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>5</sup> : C08L 5/00, A61K 31/715 // C08L 5/00C08L 5/02 C08L 5/08</p>	<p>A1</p>	<p>(11) International Publication Number: WO 90/10031 (43) International Publication Date: 7 September 1990 (07.09.90)</p>
<p>(21) International Application Number: PCT/SE90/00117 (22) International Filing Date: 21 February 1990 (21.02.90) (30) Priority data: 8900586-2 21 February 1989 (21.02.89) SE (71) Applicant (for all designated States except US): PHARMA- CIA AB [SE/SE]; S-751 82 Uppsala (SE). (72) Inventors; and (75) Inventors/Applicants (for US only) : LINDBLAD, Gert [SE/ SE]; Gosselmansgatan 1, S-271 33 Ystad (SE). BUCK- LEY, Peter [GB/SE]; Gläntvägen 5, S-752 56 Uppsala (SE). (74) Agents: SVANSTRÖM, Pär et al.; Pharmacia AB, S-751 82 Uppsala (SE).</p>		<p>(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US.  Published With international search report.</p>
<p>(54) Title: COMPOSITION AND METHOD FOR PREVENTION OF ADHESIONS BETWEEN BODY TISSUES  (57) Abstract  A composition for the prevention of adhesions between body tissues after surgical operation, containing dextran and hyaluronic acid. The invention further claims the use of the said components for the preparation of such a composition as well as its use as an agent for the prevention of adhesions.</p>		

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauritania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Faso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	HU	Hungary	NO	Norway
BJ	Benin	IT	Italy	RO	Romania
BR	Brazil	JP	Japan	SD	Sudan
CA	Canada	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LI	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark				

Composition and method for prevention of adhesions between  
body tissues

---

This invention relates to novel compositions containing a combination of hyaluronic acid and dextran and to their use as an agent for preventing adhesions, e.g. in order to avoid problems caused by unwanted adhesions between tissue surfaces.

Many surgical operations are complicated by the formation of unwanted adhesions between body tissues. Indeed, the effective prevention of adhesions is often an essential prerequisite for the ultimate success of the surgical procedure. Examples of surgery where adhesions are common and troublesome complications include abdominal surgery, where peritoneal adhesions between the intestines and/or abdominal wall may seriously impair gastrointestinal function; in urogenital surgery, where adhesions may occlude or otherwise impair the normal function of the ureters, bladder, uterus, fallopian tubes, etc, and in neurosurgery, where excessive granulation tissue may affect nerve function. In tendon surgery, the tendon and its sheath or other adjacent tissue will often tend to grow to a state of mutual adhesion during the postoperative period of immobilization and healing.

Considerable efforts have been made, without success, to prevent this problem by using various suturing techniques and passive movement of the tendon during the healing process. In microsurgery of the eye and inner ear, too, the prevention of adhesions may be of paramount importance. In thoracic and open heart surgery, the number of re-operation cases has been increasing, which has particularly highlighted the problem of pericardial and retrosternal adhesions. After heart surgery, adhesions often form between the epicardium and surrounding structures such as the pericardium, mediastinal fat, pleura and sternum. These adhesions make re-operations both difficult and hazardous. They increase the

- 2 -

risk of damage to the heart during resternotomy and obscure the underlying coronary anatomy. Tight pericardial adhesions may also tend to cause coronary artery narrowing and to thus impair myocardial function.

One way of trying to prevent adhesions is based on holding apart the surfaces of tissues for a sufficient period of time after surgery. This can be achieved by placing some form of a barrier between the surfaces. Later this barrier can be removed either by a minor operation or, preferably, by natural in vivo degradation and phagocytosis.

One example of such a suitable barrier with inbuilt biodegradability is given in Swedish patent 456346 which describes a biocompatible gel of hyaluronic acid.

The above mentioned gel or film is one example of a material having a reasonable degree of mechanical strength. But in some cases, for example in hip surgery, demands in this respect are greater and a number of synthetic materials such as prostheses of plastic or titanium etc have been developed for such applications.

In other cases, however, it may be difficult to apply a pre-shaped material so that it covers all essential surfaces; and it may be especially difficult to hold such a material in place for a sufficiently long period of time. In such situations materials in liquid form are preferable.

Among the substances in liquid form which have been advocated and tested as adhesion prophylaxis agents, certain polysaccharides deserve special mentioning, especially glycosaminoglycans such as hyaluronic acid.

Hyaluronic acid is available within a wide molecular weight interval, depending upon the source material and purification method. Highly purified hyaluronic acid of a weight average molecular weight ( $\bar{M}_w$ ) exceeding 750,000 is described by

Balazs in US patent 4141973 and a hyaluronic acid preparation of a  $\bar{M}_w$  of about 3 millions (Healon<sup>R</sup> from Pharmacia AB, Uppsala, Sweden) is commercially available.

In the patent mentioned above (US 4141973), Balazs indicates a number of applications for the product, including its use to prevent adhesions, and refers to some of the medical applications mentioned above. Hyaluronic acid has also been tested in various experimental models such as that of Weiss C et al (1986) which revealed good results in experimental tendon surgery. No adhesions were found in 55 % of the treated group whereas only 5 % of the control group were adhesion-free. Hyaluronic acid also had a pronounced effect on the nature of the adhesions - strong adhesions formed in only 18 % of the treated group but in 62 % of the controls.

Dextran is another polysaccharide which appears to reduce the risk of tissue adhesions in some models. This substance is well known in several therapeutic applications, e.g. as an important component of intravenous infusion solutions.

Among experimental studies which have been performed to investigate this effect of dextran, a trial by R J Robinson et al 1984 on prevention of pericardial adhesions is worthy of special mention. The work was performed on rabbits, whereby one group received intrapericardially 6 % dextran 70 (Macrodex from Pharmacia AB, Uppsala, Sweden) and another operated group served as controls. Complete absence of adhesions was noted in 70 % of cases in the dextran group, compared with only 10 % in the control group.

It is thus clear that prior art literature indicates that both hyaluronic acid and dextran are able to reduce the risk of postoperative adhesion complications. In certain very complicated surgical operations, however, the possibility of achieving a final success may be greatly reduced, down to zero, due to adhesion formation. In such cases, an only

partial reduction of this risk is not clinically sufficient; every effort must thus be made to completely eliminate this risk.

In this connection we have particularly studied pericardial adhesions in an attempt to resolve this problem. The experimental evaluation has been performed on a rabbit model analogous to that used by R J Robinson et al (1984) but with some very important differences: First, we induced a more pronounced standard tissue injury; and, secondly, we submitted the exposed surfaces to longer and more intensive drying. The subsequent experiments yielded very interesting results - it was evident that hyaluronic acid had a good effect (but did not prevent adhesions in all cases) whereas dextran in our standardized model provided no protection at all.

A composition containing both dextran and hyaluronic acid provided virtually complete protection against adhesion in this particular standardized model. The effect was substantially better than that of hyaluronic acid alone and, as mentioned above, dextran alone provided no protection at all. A clear synergistic effect was thus noted.

The present invention relates to a novel composition in liquid form for the prevention of adhesions between body tissues, particularly in surgical operations as, for example, in thoracic or heart surgery. The composition contains dextran and hyaluronic acid or hyaluronate or a derivative such as sulphated or polysulphated hyaluronate, hyaluronate ester (see EP 265 116) or hyaluronate which has been otherwise chemically modified in a minor way, for example as described in US 4713448.

We prefer the dextran content of the composition to lie between 1 and 35 %, preferably between 4 and 35 %, and especially 7 to 20 % w/w and the hyaluronate content to lie

between 0.5 and 6 %, preferably 0.8 to 2 %, and especially 0.8 -1.5 weight percent, in both cases calculated as percent of the composition. The molecular weights of both dextran and hyaluronic acid may vary within wide limits but the preferred ranges are 30,000 - 75,000 and 500,000 - 6,000,000, respectively.

It is known that solutions of high molecular weight dextran may cause anaphylactic reactions on injection and in addition that such reactions can be eliminated or at least minimized by administration of a low molecular weight hapten-dextran. This can be achieved either by preinjection or by simultaneous injection of the monovalent hapten-dextran, see e.g. von Messmer et al (1980). The compositions of this invention may therefore contain additives like hapten-dextran or alternatively such substances may be preinjected. For this reason, in the experimental studies presented below we have added hapten-dextran in a quantity corresponding to 30 % of the quantity of high molecular weight dextran contained in the composition.

If it is considered suitable to administer a pharmaceutical drug into the space in which adhesions are to be prevented, this may naturally be performed by adding the drug to the adhesion preventing compositions of the invention. Examples of such additives include local anaesthetics, corticosteroids, etc, etc, which may be expected to thus become effective according to a more or less "slow-release" mode of action.

Naturally, the compositions suitable as adhesion prophylaxis agents may contain other physiologically preferable polysaccharides such as carboxymethylcellulose (CMC), hydroxyethyl starch or other glycosaminoglycans (GAG) so that the above described properties are achieved even if a minor part of the hyaluronic acid or dextran is thus replaced.

The invention furthermore relates to the use of dextran and/or hyaluronate, particularly within the molecular weight limits specified above, for the preparation of compositions for preventing adhesions between body tissues where the contents of the two components in the composition lie within the above specified ranges.

Apart from dextran and hyaluronic acid, the composition contains water and possibly physiologically preferable salts and buffering agents as, for example, sodium chloride and phosphate buffer. Throughout this text the term "hyaluronic acid" has been used as according to general practice, to denote the substance. Naturally hyaluronate (e.g. sodium hyaluronate), which is the actual form at physiological pH values (around pH 7), is considered to be equivalent.

According to a yet further aspect of the invention, we provide a method of preventing adhesions between body tissues, whereby a dextran-hyaluronic acid composition, as specified above, in a quantity suitable for the actual space in which it is to be administered, is implanted in connection with a surgical operation.

#### Experiment

Studies on pericardial adhesions were performed on rabbits (Sw Loop, weight 3 - 35 kg). After the animals had been anesthetized with Hypnorm (1.0 ml/kg; Johnson Pharmaceuticals), the pericardium was exposed by an incision through the breast bone (sternum). The rib cage was held open with the aid of a thorax brace and the pericardium was thereafter opened by means of a 1 - 1.5 cm incision. Two to four cotton swabs were used to absorb all the fluid present within the pericardium. A Proxa brush No. 622 Butler Long was thereafter used to injure the heart and the wall of the pericardium. The brush was drawn back and forth about 10 times. Thereafter a tube was inserted through the incision and the tissue surfaces were dried by blowing in oxygen at a pressure of 1.5 bar for 10 minutes.



Finally, ca 1 ml of autologous blood together with the test composition was inserted into the space between the heart and the pericardium, whereupon the incision was closed with a 7-0 Prolene suture. Thereafter the rib cage, musculature and outer skin were sewed together. The animals were then allowed to waken and live for 2 - 3 weeks, after which they were killed. The heart was then carefully removed in order to assess the extent to which the surface area of the heart (in percent) adhered to the surrounding pericardium and to assess the degree of adhesions in each instance.

The adhesions were assessed on a scale of 1-4 (1 none, 2 light, 3 considerable, and 4 profuse adhesions).

During postoperative care, 0.3 ml Pethidine ACO was given 2 - 3 times per day (i.e. every 4 - 5 hours).

## Results

Table 1

<u>Exp. no</u>	<u>Rabbit no</u>	<u>Treatment</u>	<u>Degree of adh</u>	<u>% adh to heart</u>
2	1891-8	Control	3 (considerable)	40
2	1892-8	Control	3-	45
2	1893-8	Control	3	30
2	1894-8	Control	2+-3	30
2	1895-8	Control	3	30
2	1896-8	Control	2	10
2	1897-8	Control	3+	40
2	1901-8	Control	4 (profuse)	50
2	1998-8	Control	2 (light)	10
2	1899-8	Control	4+	100
2	1900-8	Control	4	75
2	1903-8	Control	4+	60
3a	13008-8	Control	4	90
3a	13025-8	Control	3	45
3a	13024-8	Control	3	35
3b	12558-8	Control	3	10
3b	12564-8	Control	4	75
3b	12592-8	Control	4	60
3b	12591-8	Control	1 (none)	30

Cont. Table 1

<u>Exp. no</u>	<u>Rabbit no</u>	<u>Treatment</u>	<u>Grade of adh</u>	<u>% adh to heart</u>
4	12574-8	Control	4	100
4	12590-8	Control	4	85
4	12585-8	Control	3	30
4	12580-8	Control	3	25
5	11878-8	Control	3	50
5	11434-8	Control	4	100
5	13439-8	Control	3	35
4	12569-8	0,8 ml FYSKOSAL (0,15M NaCL)	3	40
4	12577-8	0,8 ml "-	4	75
5	13436-8	Fyskosal	4	80
5	13429-8	Fyskosal	2+	25
5	13435	Fyskosal	4	80
3a	13010-8	0,8 ml 1% Na-hyaluronat	2+	5
3a	13016-8	0,8 ml "	3+	2
3a	13017-8	0,8 ml "	1	0
3a	13021-8	0,8 ml "	1	0
3b	12559-8	0,8 ml "	1	0
3b	12563-8	0,8 ml "	1	0
3b	12565-8	0,8 ml "	1	0
3b	12570-8	0,8 ml "	3	5
3b	12573-8	0,8 ml "	1	0
3b	12583-8	0,8 ml "	3	10
3a	13009-8	0,8 ml 1%HA10%DX70	1	0
3a	13018-8	0,8 ml "-	1	0
3a	13014-8	0,8 ml "-	1	0
3b	12561-8	0,8 ml "-	2+	2
3b	12566-8	0,8 ml "-	1	0
3b	12567-8	0,8 ml "-	1	0
3b	12568-8	0,8 ml "-	1	0
3b	12571-8	0,8 ml "-	1	0
3b	12582-8	0,8 ml "-	1	0
4	12585-8	0,8 ml 0,5%HA10%DX70 +3%DX1	3	50
4	12579-8	0,8 ml "-	1	0
4	12575-8	0,8 ml "-	2	5
4	12572-8	0,8 ml "-	3	1
4	11876-8	0,8 ml "-	1	0
4	12588-8	0,8 ml "-	3	3
4	12586-8	0,8 ml 10%DX70	2	40
4	12560-8	0,8 ml "-	3	20
4	12576-8	0,8 ml "-	3	20
4	11872-8	0,8 ml "-	3	35
4	12578-8	0,8 ml "-	3	40
4	12581-8	0,8 ml "-	3	65

Cont. Table 1

<u>Exp. no</u>	<u>Rabbit no</u>	<u>Treatment</u>	<u>Grade of adh</u>	<u>% adh to heart</u>
5	13437-8	0,8 ml 1%HA5%DX70	2	5
5	13438-8	0,8 ml --	1	0
5	13432-8	0,8 ml --	1	0
5	13440-8	0,8 ml --	1	0
5	13443-8	0,8 ml --	3	20
5	11871-8	0,8 ml --	1	0
5	11877-8	1,6 ml 0,5%HA	2	1
5	13441-8	1,6 ml --	1	0
5	13433-8	1,6 ml --	3	35
5	13442-8	1,6 ml --	1	0
5	10953-8	1,6 ml --	2+	10

As is evident from the results above, the effect of dextran was not significantly different from that of the controls whereas hyaluronic acid alone had a distinct effect, although even in this group adhesions were recorded in 40 % of the cases, albeit with limited surface attachment. However, in the group which received the composition according to the invention, it was possible to prevent adhesions in 90 % of the cases and the only adhesion noted was very minor and located at the operation incision.

The compositions according to the invention have thus proved to have a surprising capability of preventing postoperative complications in the form of adhesions, and the result thus offers considerable promise for human trials.

### References

Weiss C et al (1986)

The role of Na-hylan in reducing postsurgical tendon adhesions  
Bull Hosp Jt Dis Orthop Inst 46(1), 9-15

Robison Robert J et al (1984)

Prevention of Pericardial Adhesions with Dextran 70  
The Annals of Thoracic Surgery 37(6), 488-490

Von Messmer K et al (1980)

Anaphylaktoide Reaktionen nach Dextran  
Allergologie, Jahrgang 3, Nr 2/1980, Sonderausgabe, 17-24.

Claims

1. A composition for use in surgical operations to prevent adhesions between tissue surfaces, said composition being comprised of an admixture of dextran and hyaluronic acid.
2. A composition according to Claim 1, which contains dextran in an amount of 1 to 35 % and hyaluronic acid in an amount of 0.5 to 6 %.
3. A composition according to Claim 2, which contains dextran having a weight average molecular weight within the range of 30,000 to 75,000 and hyaluronic acid having a weight average molecular weight within the range 500,000 to 6,000,000.
4. A composition according to Claims 1 to 3, which additionally contains a hapten dextran.
5. The use of dextran and hyaluronic acid for the preparation of an aqueous composition for preventing adhesions between tissue surfaces, whereby the dextran content of the composition lies within the range 1 - 35 % and the hyaluronic acid content of the composition lies within the range 0.5 - 6 %.
6. The use of dextran and hyaluronic acid for the preparation of a composition according to Claim 5, in which the dextran has a weight average molecular weight within the range 30,000 - 75,000 and the hyaluronic acid has a weight average molecular weight within the range of 500,000 to 6,000,000.

7. Method for preventing adhesion between tissue surfaces, characterized in that a composition according to any of the Claims 1 to 4 is implanted into the space in which adhesions are to be prevented.
8. Method according to Claim 7, in which the composition is implanted in connection with a surgical operation.

# INTERNATIONAL SEARCH REPORT

International Application No PCT/SE 90/00117

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) <sup>6</sup> According to International Patent Classification (IPC) or to both National Classification and IPC IPC5: C 08 L 5/00, A 61 K 31/715/. C 08 L 5/00, 5:02, 5:08														
<b>II. FIELDS SEARCHED</b> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Minimum Documentation Searched<sup>7</sup></div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 25%; border-bottom: 1px solid black;">Classification System</th> <th style="border-bottom: 1px solid black;">Classification Symbols</th> </tr> <tr> <td style="height: 40px; vertical-align: bottom; padding: 5px;">IPC5</td> <td style="padding: 5px;">C 08 L; A 61 K; C 08 B</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Documentation Searched other than Minimum Documentation to the extent that such Documents are included in Fields Searched<sup>8</sup></div> <p style="padding: 5px;">SE,DK,FI,NO classes as above</p>			Classification System	Classification Symbols	IPC5	C 08 L; A 61 K; C 08 B								
Classification System	Classification Symbols													
IPC5	C 08 L; A 61 K; C 08 B													
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; border-bottom: 1px solid black;">Category<sup>10</sup></th> <th style="border-bottom: 1px solid black;">Citation of Document,<sup>11</sup> with indication, where appropriate, of the relevant passages<sup>12</sup></th> <th style="width: 15%; border-bottom: 1px solid black;">Relevant to Claim No.<sup>13</sup></th> </tr> <tr> <td style="vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">Eur.surg.Res., Vol. 9, 1977 D. Bergqvist and K.-E. Arfors: "Effect of Dextran and Hyaluronic Acid on the Development of Postoperative Peritoneal Adhesions in Experimental Animals ", see page 321 - page 325 page 323, last paragraph - page 324</td> <td style="vertical-align: top; text-align: center; padding: 5px;">1,7,8</td> </tr> <tr> <td style="vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">Dialog Information Services, File 154, Medline 83-90, Dialog accession no. 86270497, Green, S et al: "The inhibition of flexor tendon adhesions", Bull Hosp Jt Dis Orthop Inst; 46 (1) p 16-21</td> <td style="vertical-align: top; text-align: center; padding: 5px;">1</td> </tr> <tr> <td style="vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">Bull Hosp Jt Dis Orthop Inst., Vol. 46, No. 1, 1986 Charles Weiss et al: "The Role of Na-hylan in Reducing Postsurgical Tendon Adhesions ", see page 9 - page 15 abstract, conclusions page 15</td> <td style="vertical-align: top; text-align: center; padding: 5px;">1</td> </tr> </table>			Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>	A	Eur.surg.Res., Vol. 9, 1977 D. Bergqvist and K.-E. Arfors: "Effect of Dextran and Hyaluronic Acid on the Development of Postoperative Peritoneal Adhesions in Experimental Animals ", see page 321 - page 325 page 323, last paragraph - page 324	1,7,8	A	Dialog Information Services, File 154, Medline 83-90, Dialog accession no. 86270497, Green, S et al: "The inhibition of flexor tendon adhesions", Bull Hosp Jt Dis Orthop Inst; 46 (1) p 16-21	1	A	Bull Hosp Jt Dis Orthop Inst., Vol. 46, No. 1, 1986 Charles Weiss et al: "The Role of Na-hylan in Reducing Postsurgical Tendon Adhesions ", see page 9 - page 15 abstract, conclusions page 15	1
Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>												
A	Eur.surg.Res., Vol. 9, 1977 D. Bergqvist and K.-E. Arfors: "Effect of Dextran and Hyaluronic Acid on the Development of Postoperative Peritoneal Adhesions in Experimental Animals ", see page 321 - page 325 page 323, last paragraph - page 324	1,7,8												
A	Dialog Information Services, File 154, Medline 83-90, Dialog accession no. 86270497, Green, S et al: "The inhibition of flexor tendon adhesions", Bull Hosp Jt Dis Orthop Inst; 46 (1) p 16-21	1												
A	Bull Hosp Jt Dis Orthop Inst., Vol. 46, No. 1, 1986 Charles Weiss et al: "The Role of Na-hylan in Reducing Postsurgical Tendon Adhesions ", see page 9 - page 15 abstract, conclusions page 15	1												
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><sup>10</sup> * Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p> </div> </div>														
<b>IV. CERTIFICATION</b> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">           Date of the Actual Completion of the International Search  <b>21st May 1990</b> </td> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">           Date of Mailing of this International Search Report  <b>1990 -05- 2 3</b> </td> </tr> <tr> <td style="border-bottom: 1px solid black; padding: 5px;">           International Searching Authority  <b>SWEDISH PATENT OFFICE</b> </td> <td style="border-bottom: 1px solid black; padding: 5px;">           Signature of Authorized Officer  <i>Agneta Osterman Wallin</i>  <b>Agneta Osterman Wallin</b> </td> </tr> </table>			Date of the Actual Completion of the International Search <b>21st May 1990</b>	Date of Mailing of this International Search Report <b>1990 -05- 2 3</b>	International Searching Authority <b>SWEDISH PATENT OFFICE</b>	Signature of Authorized Officer <i>Agneta Osterman Wallin</i> <b>Agneta Osterman Wallin</b>								
Date of the Actual Completion of the International Search <b>21st May 1990</b>	Date of Mailing of this International Search Report <b>1990 -05- 2 3</b>													
International Searching Authority <b>SWEDISH PATENT OFFICE</b>	Signature of Authorized Officer <i>Agneta Osterman Wallin</i> <b>Agneta Osterman Wallin</b>													

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
A	<p>Bull Hosp Jt Dis Orthop Inst, Vol. 47, No. 1, 1987  Charles Weiss et al: "The Role of Na-hylan in Reducing Postsurgical Tendon Adhesions: Part 2", see page 31 - page 39  conclusions page 38</p> <p>--</p>	1
A	<p>Annals of thoracic surgery, Vol. 37, No. 6, 1984  Robert J. Robison et al: "Prevention of Pericardial Adhesions with Dextran 70 ", see page 488 - page 490</p> <p>--</p> <p>-----</p>	1



ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.PCT/SE 90/00117

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
The members are as contained in the Swedish Patent Office EDP file on 90-05-07  
The Swedish Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date

**THIS PAGE BLANK (USPTO)**